Muscle fatigue associated with brain inflammation could be prevented by modulating certain cytokines. Researchers at Washington University in St. Louis (WUSTL) have studied inflammation in the CNS in infection models of Escherichia coli, SARS-CoV-2 and amyloid-β toxicity, unveiling its impact on motor function, the role of IL-6 in this process and how to mitigate it in chronic disease. Read More
Cigarette smoke, the main cause of chronic obstructive lung disease, is considered a significant contributor of neuroinflammation, potentially leading to cognitive impairment and neurodegeneration. About 61% of individuals with chronic obstructive pulmonary disease have neurocognitive dysfunction. Read More
Plexium Inc. has reported the discovery and preclinical characterization of PLX-3618, a novel monovalent direct degrader of BRD4 being developed for the treatment of cancer. Read More
Synaptogenix Inc. has entered into a new collaboration agreement with LSU Health New Orleans’ Neuroscience Center of Excellence for preclinical testing of the company’s polyunsaturated fatty acid (PUFA) analogues. Read More
Acrivon Therapeutics Inc. has disclosed membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer. Read More
Previous studies have demonstrated that the natural product isotoosendanin (ITSN) inhibited triple-negative breast cancer (TNBC) metastasis by preventing epithelial-mesenchymal transition (EMT) and lamellipodia formation regulated by the TGF-β–Smad2/3 signaling pathway in TNBC cells through directly binding to TGF-β receptor type 1 (TGF-βR1). Read More
From no hope to viable treatments, BioWorld is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld team is ‘always on the lookout for what's next.’ Read More
Nurexone Biologic Inc. has announced preliminary results from a small-scale controlled study at Sheba Medical Center exploring the use of nanodrug Exopten for optic nerve recovery in a rat model. An optic nerve crush (ONC) model was used to simulate conditions such as glaucoma, where the optic nerve is damaged, resulting in impaired vision. Read More
Merck Sharp & Dohme LLC has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others. Read More
The development of KRAS G12D inhibitors has proven challenging to date and, different from anti-KRAS G12C strategies, no compound targeting KRAS G12D mutation has been approved so far. Read More
Researchers at Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM) and Université Côte d'Azur have divulged amidinourea derivatives reported to be useful for the treatment of cancer, in particular for BRAF inhibitor-resistant melanoma. Read More
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described oxime-containing compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, transplant rejection and neurodegeneration, among others. Read More
Breast cancer is the leading cancer malignancy in women and triple-negative breast cancer (TNBC) is among the most aggressive types as it is insensitive to endocrine and HER2-targeted therapy because it lacks all three hormonal receptors. Read More
